Bio-Connect

CD19 Antibody (clone C19/366)

LS-C389842
LifeSpan BioSciences
ApplicationsFlow Cytometry, ImmunoFluorescence
Product group Antibodies
ReactivityHuman
TargetCD19
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    LifeSpan BioSciences
  • Product Name
    CD19 Antibody (clone C19/366)
  • Delivery Days Customer
    23
  • Application Supplier Note
    CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.. Flo (0.5 - 1 µg/10E6 cells), IF (0.5 - 1 µg/ml) CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
  • Applications
    Flow Cytometry, ImmunoFluorescence
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    C19/366
  • Concentration
    0.2 mg/ml
  • Conjugate
    Unconjugated
  • Estimated Purity
    ...
  • Gene ID930
  • Target name
    CD19
  • Target description
    CD19 molecule
  • Target synonyms
    B4, CVID3, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12, differentiation antigen CD19
  • Host
    Mouse
  • Isotype
    IgG1
  • Reactivity
    Human
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    41116161